Treatment of Acute Ischemic Stroke With Rt-PA Combined With Edaravone Dexborneol - Trial NCT06248242
Access comprehensive clinical trial information for NCT06248242 through Pure Global AI's free database. This Phase 4 trial is sponsored by The Second Hospital of Hebei Medical University and is currently Recruiting. The study focuses on Acute Ischemic Stroke. Target enrollment is 400 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
The Second Hospital of Hebei Medical University
Timeline & Enrollment
Phase 4
Jun 01, 2021
Jun 30, 2024
Primary Outcome
Comparison of neurological function between the two groups
Summary
In this study, a multicenter, randomized, controlled, prospective cohort study was conducted
 to observe the effect of Edaravone Dexborneol on the incidence and outcome of bleeding
 transformation after thrombolysis in acute ischemic stroke. To explore the methods to reduce
 the dilemma of bleeding transformation after thrombolysis, and to dynamically detect the
 changes of the main links causing bleeding transformation such as blood-brain barrier damage,
 local immune response activation and so on. To explore the mechanism of Edaravone Dexborneol
 in reducing bleeding transformation. It is proved that Edaravone Dexborneol combined with
 thrombolytic therapy can reduce the risk of bleeding and transformation after thrombolysis
 and improve the safety of thrombolysis. Secondly, it can improve the early recanalization
 rate of ischemic stroke patients after thrombolytic therapy, and effectively protect the
 integrity of the blood-brain barrier.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06248242
Non-Device Trial